- What is the clinical effectiveness and safety of delta-9-tetrahydrocannabinol/cannabidiol for the treatment of adult patients with chronic non-cancer pain or neuropathic pain?
- What are the evidence-based guidelines relating to the use of delta-9-tetrahydrocannabinol/cannabidiol for adult patients with chronic non-cancer pain or neuropathic pain?
Five systematic reviews, including two with meta-analyses, were identified relating to the clinical effectiveness of delta-9-tetrahydrocannabinol/cannabidiol (THC:CBD) buccal spray for the treatment of chronic neuropathic or non-cancer pain. Based on the identified published literature, THC:CBD buccal spray may be associated with favourable short-term patient outcomes, including reduced levels of perceived pain and a good tolerability, when compared with placebo therapy. However, sustained benefit of short-term clinical outcomes and safety over a longer term is unclear, and the clinical effectiveness of THC:CBD oral spray in comparison with other pharmacologic treatments is currently lacking.One evidence-based guideline was identified that recommends third-line use of THC:CBD buccal spray for patients uncontrolled on drug therapy in the management of chronic neuropathic pain.